X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GLENMARK PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GLENMARK PHARMA TORRENT PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 27.3 12.0 227.2% View Chart
P/BV x 5.2 3.2 163.5% View Chart
Dividend Yield % 1.0 0.4 275.9%  

Financials

 TORRENT PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
GLENMARK PHARMA
Mar-17
TORRENT PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,768993 178.0%   
Low Rs1,186729 162.6%   
Sales per share (Unadj.) Rs346.1325.5 106.3%  
Earnings per share (Unadj.) Rs55.239.3 140.4%  
Cash flow per share (Unadj.) Rs73.348.7 150.6%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %0.90.2 408.2%  
Book value per share (Unadj.) Rs257.1159.2 161.5%  
Shares outstanding (eoy) m169.22282.17 60.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.32.6 161.3%   
Avg P/E ratio x26.821.9 122.1%  
P/CF ratio (eoy) x20.117.7 113.8%  
Price / Book Value ratio x5.75.4 106.2%  
Dividend payout %25.45.1 498.6%   
Avg Mkt Cap Rs m249,887242,991 102.8%   
No. of employees `00011.813.0 90.9%   
Total wages/salary Rs m9,93416,408 60.5%   
Avg. sales/employee Rs Th4,971.57,083.9 70.2%   
Avg. wages/employee Rs Th843.21,265.4 66.6%   
Avg. net profit/employee Rs Th792.4855.1 92.7%   
INCOME DATA
Net Sales Rs m58,56991,857 63.8%  
Other income Rs m2,233374 597.6%   
Total revenues Rs m60,80292,230 65.9%   
Gross profit Rs m13,77320,367 67.6%  
Depreciation Rs m3,0692,644 116.1%   
Interest Rs m2,0562,373 86.6%   
Profit before tax Rs m10,88115,724 69.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,5453,827 40.4%   
Profit after tax Rs m9,33611,088 84.2%  
Gross profit margin %23.522.2 106.1%  
Effective tax rate %14.224.3 58.3%   
Net profit margin %15.912.1 132.1%  
BALANCE SHEET DATA
Current assets Rs m53,84168,746 78.3%   
Current liabilities Rs m31,61227,027 117.0%   
Net working cap to sales %38.045.4 83.6%  
Current ratio x1.72.5 67.0%  
Inventory Days Days9785 114.3%  
Debtors Days Days8496 87.7%  
Net fixed assets Rs m42,07924,132 174.4%   
Share capital Rs m846282 299.9%   
"Free" reserves Rs m42,65544,643 95.5%   
Net worth Rs m43,50144,925 96.8%   
Long term debt Rs m22,40845,363 49.4%   
Total assets Rs m101,250117,639 86.1%  
Interest coverage x6.37.6 82.5%   
Debt to equity ratio x0.51.0 51.0%  
Sales to assets ratio x0.60.8 74.1%   
Return on assets %11.311.4 98.3%  
Return on equity %21.524.7 87.0%  
Return on capital %19.619.1 102.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06656,152 35.7%   
Fx outflow Rs m5,3048,084 65.6%   
Net fx Rs m14,76248,068 30.7%   
CASH FLOW
From Operations Rs m10,1276,574 154.0%  
From Investments Rs m-7,869-7,124 110.5%  
From Financial Activity Rs m-1,9185,432 -35.3%  
Net Cashflow Rs m2121,992 10.6%  

Share Holding

Indian Promoters % 71.5 48.3 148.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 6.9 101.7%  
FIIs % 12.6 34.4 36.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 56,727 46.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 22, 2018 02:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS